Your browser doesn't support javascript.
loading
Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma.
Forero-Torres, Andres; Chandler, Jason Claud; Iyer, Swaminathan P; Kanate, Abraham S; Quinlan, Michelle; Hoever, Petra; Izquierdo, Miguel; Davis, Jaclyn; Madan, Sumit.
Affiliation
  • Forero-Torres A; University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Chandler JC; West Cancer Center, Germantown, Tennessee, USA.
  • Iyer SP; Houston Methodist Cancer Center, Houston, Texas, USA.
  • Kanate AS; West Virginia University, Morgantown, West Virginia, USA.
  • Quinlan M; Novartis Oncology, East Hanover, New Jersey, USA.
  • Hoever P; Novartis Pharma AG, Basel, Switzerland.
  • Izquierdo M; Cancer Therapy & Research Center, San Antonio, Texas, USA.
  • Davis J; Novartis Oncology, East Hanover, New Jersey, USA.
  • Madan S; Cancer Therapy & Research Center, San Antonio, Texas, USA.
Clin Pharmacol Drug Dev ; 11(9): 1099-1109, 2022 09.
Article in En | MEDLINE | ID: mdl-35819310
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, B-Cell / Antibodies, Monoclonal, Humanized / Bendamustine Hydrochloride Type of study: Clinical_trials Limits: Humans Language: En Journal: Clin Pharmacol Drug Dev Year: 2022 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, B-Cell / Antibodies, Monoclonal, Humanized / Bendamustine Hydrochloride Type of study: Clinical_trials Limits: Humans Language: En Journal: Clin Pharmacol Drug Dev Year: 2022 Type: Article Affiliation country: United States